These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

298 related articles for article (PubMed ID: 8912537)

  • 1. NM-23 H1 immunohistochemistry is not useful as predictor of metastatic potential of colorectal cancer.
    Lindmark G
    Br J Cancer; 1996 Nov; 74(9):1413-8. PubMed ID: 8912537
    [TBL] [Abstract][Full Text] [Related]  

  • 2. NM23 gene product expression does not predict lymph node metastases or survival in young patients with colorectal cancer.
    Heys SD; Langlois N; Smith IC; Walker LG; Eremin O
    Oncol Rep; 1998; 5(3):735-9. PubMed ID: 9538187
    [TBL] [Abstract][Full Text] [Related]  

  • 3. NM23-H1 immunostaining is inversely associated with tumour staging but not overall survival or disease recurrence in colorectal carcinomas.
    Cheah PY; Cao X; Eu KW; Seow-Choen F
    Br J Cancer; 1998 Apr; 77(7):1164-8. PubMed ID: 9569056
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Elevated nm23 protein expression is correlated with diminished progression-free survival in patients with epithelial ovarian carcinoma.
    Srivatsa PJ; Cliby WA; Keeney GL; Dodson MK; Suman VJ; Roche PC; Podratz KC
    Gynecol Oncol; 1996 Mar; 60(3):363-72. PubMed ID: 8774640
    [TBL] [Abstract][Full Text] [Related]  

  • 5. DNA ploidy and S-phase fraction, but not p53 or NM23-H1 expression, predict outcome in colorectal cancer patients. Result of a 5-year prospective study.
    Bazan V; Migliavacca M; Zanna I; Tubiolo C; Corsale S; Calò V; Amato A; Cammareri P; Latteri F; Grassi N; Fulfaro F; Porcasi R; Morello V; Nuara RB; Dardanoni G; Salerno S; Valerio MR; Dusonchet L; Gerbino A; Gebbia N; Tomasino RM; Russo A
    J Cancer Res Clin Oncol; 2002 Dec; 128(12):650-8. PubMed ID: 12474051
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nm23-H1 protein, DNA-ploidy and S-phase fraction in relation to overall survival and disease free survival in transitional cell carcinoma of the bladder.
    Alderisio M; Cenci M; Valli C; Russo A; Bazan V; Dardanoni G; Cucciarre S; Carreca I; Macaluso MP; Tomasino RM; Vecchione A
    Anticancer Res; 1998; 18(6A):4225-30. PubMed ID: 9891471
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [nm23 gene product/NDPK expression and its clinical significance in human colorectal carcinoma].
    Wang C; Zhang X; Yang F
    Zhonghua Bing Li Xue Za Zhi; 1995 Dec; 24(6):356-8. PubMed ID: 8732091
    [TBL] [Abstract][Full Text] [Related]  

  • 8. nm23-H1 protein immunoreactivity in laryngeal carcinoma.
    Lee CS; Redshaw A; Boag G
    Cancer; 1996 Jun; 77(11):2246-50. PubMed ID: 8635091
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Overexpression of nm23-H1 and nm23-H2 genes in colorectal carcinomas and loss of nm23-H1 expression in advanced tumour stages.
    Martinez JA; Prevot S; Nordlinger B; Nguyen TM; Lacarriere Y; Munier A; Lascu I; Vaillant JC; Capeau J; Lacombe ML
    Gut; 1995 Nov; 37(5):712-20. PubMed ID: 8549951
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nm23-H1 expression does not predict clinical survival in colorectal cancer patients.
    Dusonchet L; Corsale S; Migliavacca M; Calò V; Bazan V; Amato A; Cammareri P; Totaro MS; Agnese V; Cascio S; La Rocca G; Sisto PS; Dardanoni G; Valerio MR; Grassi N; Latteri S; Cajozzo M; Buscemi M; Castorina S; Morello V; Tomasino RM; Gebbia N; Russo A
    Oncol Rep; 2003; 10(5):1257-63. PubMed ID: 12883690
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunohistochemical evaluation of nm23-H1 gene product in transitional cell carcinoma of the bladder.
    Nakopoulou LL; Constandinides CA; Tzonou A; Lazaris AC; Zervas A; Dimopoulos CA
    Histopathology; 1996 May; 28(5):429-35. PubMed ID: 8735718
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression of nm23-H1 predicts lymph node involvement in colorectal carcinoma.
    Tannapfel A; Köckerling F; Katalinic A; Wittekind C
    Dis Colon Rectum; 1995 Jun; 38(6):651-4. PubMed ID: 7774480
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunohistochemical examinations (Ki67, p53, nm23) and DNA cytophotometry in bladder cancer.
    Krause FS; Feil G; Bichler KH
    Anticancer Res; 2000; 20(6D):5023-8. PubMed ID: 11326661
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reappraisal of the role of NM23-H1 in colorectal cancers.
    Lee JC; Lin YJ; Chow NH; Wang ST
    J Surg Oncol; 2001 Jan; 76(1):58-62. PubMed ID: 11223826
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Variability of nm23-H1/NDPK-A expression in human lymphomas and its relation to tumour aggressiveness.
    Aryee DN; Simonitsch I; Mosberger I; Kos K; Mann G; Schlögl E; Pötschger U; Gadner H; Radaszkiewicz T; Kovar H
    Br J Cancer; 1996 Dec; 74(11):1693-8. PubMed ID: 8956779
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of nm23-H1 and nm23-H2 protein in endometrial carcinoma.
    Watanabe J; Sato Y; Kuramoto H; Kameya T
    Br J Cancer; 1995 Dec; 72(6):1469-73. PubMed ID: 8519661
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Early stage human colorectal cancer: prognostic value of nm23-H1 protein overexpression.
    Indinnimeo M; Giarnieri E; Stazi A; Cicchini C; Brozzetti S; Valli C; Carreca I; Vecchione A
    Cancer Lett; 1997 Jan; 111(1-2):1-5. PubMed ID: 9022121
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High level of Nm23-H1 gene expression is associated with local colorectal cancer progression not with metastases.
    Zeng ZS; Hsu S; Zhang ZF; Cohen AM; Enker WE; Turnbull AA; Guillem JG
    Br J Cancer; 1994 Nov; 70(5):1025-30. PubMed ID: 7947079
    [TBL] [Abstract][Full Text] [Related]  

  • 19. nm23-H1 expression and loss of heterozygosity in colon adenocarcinoma.
    Kapitanović S; Cacev T; Berković M; Popović-Hadzija M; Radosević S; Seiwerth S; Spaventi S; Pavelić K; Spaventi R
    J Clin Pathol; 2004 Dec; 57(12):1312-8. PubMed ID: 15563674
    [TBL] [Abstract][Full Text] [Related]  

  • 20. nm23-H1 expression defines a high-risk subpopulation of patients with early-stage epithelial ovarian carcinoma.
    Schneider J; Pollán M; Jiménez E; Marenbach K; Martínez N; Volm M; Marx D; Meden H
    Br J Cancer; 2000 May; 82(10):1662-70. PubMed ID: 10817501
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.